Omeros reported $69.65M in Current Assets for its fiscal quarter ending in June of 2025.





Current Assets Change Date
Adma Biologics USD 575.86M 47.66M Sep/2026
Alnylam Pharmaceuticals USD 5.11B 492.49M Sep/2026
BioMarin Pharmaceutical USD 3.92B 50.99M Sep/2026
Cytokinetics USD 1.19B 21.34M Sep/2026
Gilead Sciences USD 16.55B 4.02B Sep/2026
Heron Therapeutics USD 209.11M 20.73M Sep/2026
Immunic USD 135.09M 22.75M Sep/2026
Insmed USD 1.71B 72.59M Sep/2026
Knight Therapeutics CAD 394.84M 5.86M Dec/2025
MacroGenics USD 295.08M 26.61M Sep/2026
Omeros USD 69.65M 26.53M Jun/2025
Pacira USD 10.3B 9.68B Sep/2026
Pfizer USD 45.01B 3.65B Sep/2026
Rockwell Medical USD 31.61M 1.42M Jun/2025
Sangamo BioSciences USD 49.89M 12.3M Jun/2025
Sarepta Therapeutics USD 2.27B 49.06M Sep/2026
United Therapeutics USD 2.88B 603.5M Sep/2026
Vertex Pharmaceuticals USD 11.69B 857.4M Sep/2026